JenaValve is a leading company in the transcatheter heart valve technology sector and are developing a differentiated valve system to treat aortic regurgitation and aortic stenosis.
JenaValve is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement system designed to treat patients with symptomatic, severe aortic regurgitation and aortic stenosis in high surgical risk patients. Current approved valve systems are not indicated for aortic regurgitation and do not address the specific unmet needs of the indication.
CEO
John Kilcoyne
Sub segment
Transcatheter aortic valve replacement
Location
California, United States